Ayble Health Closes $16M Series A to Expand AI‑Powered Virtual GI Platform and Autoimmune Care Services

Ayble Health, an AI‑driven virtual gastrointestinal clinic, announced a $16 million Series A financing round.

Based in Boston, Ayble Health treats a wide range of digestive disorders—including abdominal pain, bloating, constipation and weight gain—through a holistic platform that connects patients with a multidisciplinary care team, evidence‑based nutrition tools, gut‑brain behavioral therapy and continuous wellness support. The service is designed for employers, payers and healthcare providers.

The Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice. Total funds raised now exceed $27 million.

“I’ve been tracking the GI space closely for years, and what Ayble has built is different,” said Kimmy Scotti, founding and managing partner at Neon, in a statement. “Having invested early in top digital health companies, I’ve seen what it takes to build a category‑defining company in healthcare. Ayble has spent years building the clinical evidence before they scaled the business. That earns trust from the full ecosystem: health systems, payers, and most importantly, patients, and it’s what makes a durable market leader.”

The financing will be deployed across three key areas, according to Sam Jactel, founder and CEO of Ayble Health.

“First, we are advancing our machine‑learning capabilities to deliver deeper, data‑driven personalization across patient enrollment, engagement and clinical pathways,” Jactel told MedCity News. “Second, we are expanding our multidisciplinary care model beyond GI into adjacent therapeutic areas, starting with autoimmune conditions such as rheumatoid arthritis, psoriasis and autoimmune thyroid disorders. Finally, we are accelerating our commercial footprint to scale access across national health plans, large employers and major benefit platforms.”

Gastrointestinal conditions currently affect more than 70 million Americans and generate $136 billion in annual U.S. healthcare spending. Autoimmune diseases add roughly $106 billion in direct U.S. costs each year, and patients often wait up to 40 days for a specialty appointment.

These disorders also frequently overlap. A 2025 study of 141 million patients linked inflammatory bowel disease with 24 distinct autoimmune conditions.

“Traditional healthcare treats these conditions in isolated silos with 10‑minute specialty visits,” Jactel noted. “But chronic conditions don’t exist in a vacuum, and they certainly don’t stop when you leave the doctor’s office. Ayble solves this by building an evidence‑based, multidisciplinary model that treats overlapping gut and autoimmune conditions under one unified platform.”

Other notable GI‑focused digital health companies include Oshi Health, Cylinder Health and Digbi Health.

Photo: MirageC, Getty Images

Source link